![Daniel Karp](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Karp
Directeur/Bestuurslid bij
CARTESIAN GROWTH CORPORATION II
Vermogen: 927 770 $ op 31-05-2026
Profiel
Daniel Karp is currently an Independent Director at Cartesian Growth Corp.
II since 2022 and Executive Vice President-Corporate Development at Organon & Co. Former positions include Independent Director at Cartesian Growth Corp., Vice President-Worldwide Business Development at Pfizer Inc. from 2016 to 2018, and Executive Vice President-Corporate Development at Biogen, Inc. from 2018 to 2020.
Education includes an undergraduate degree from Duke University and an MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ORGANON & CO. 0,03% | 15-06-2026 | 69.548 ( 0,03% ) | 927 770 $ | 31-05-2026 |
Actieve functies van Daniel Karp
| Bedrijven | Functie | Begin |
|---|---|---|
| CARTESIAN GROWTH CORPORATION II | Directeur/Bestuurslid | 01-05-2022 |
| ORGANON & CO. | Corporate Officer/Principal | - |
Eerdere bekende functies van Daniel Karp
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01-05-2020 |
| PFIZER INC. | Corporate Officer/Principal | 01-06-2018 |
| ALVARIUM TIEDEMANN A | Directeur/Bestuurslid | - |
Opleiding van Daniel Karp
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
87
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cartesian Growth Corp.
 Cartesian Growth Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Organon & Co.
 Organon & Co. Pharmaceuticals: MajorHealth Technology Develops and delivers women health, trusted legacy brands and therapeutics | Health Technology |
Cartesian Growth Corp. II
 Cartesian Growth Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Kies MarketScreener 
